WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Debt-to-Equity : 0.14 (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Debt-to-Equity?

WuXi Biologics (Cayman)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $179 Mil. WuXi Biologics (Cayman)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $539 Mil. WuXi Biologics (Cayman)'s Total Stockholders Equity for the quarter that ended in Jun. 2023 was $5,270 Mil. WuXi Biologics (Cayman)'s debt to equity for the quarter that ended in Jun. 2023 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for WuXi Biologics (Cayman)'s Debt-to-Equity or its related term are showing as below:

WXXWY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.15 Max: 4.18
Current: 0.11

During the past 10 years, the highest Debt-to-Equity Ratio of WuXi Biologics (Cayman) was 4.18. The lowest was 0.03. And the median was 0.15.

WXXWY's Debt-to-Equity is ranked better than
56.77% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs WXXWY: 0.11

WuXi Biologics (Cayman) Debt-to-Equity Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Debt-to-Equity Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.16

0.13

0.11

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial													0.13	0.13	0.13	0.14	0.11

Competitive Comparison of WuXi Biologics (Cayman)'s Debt-to-Equity

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman)'s Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Debt-to-Equity falls into.

WuXi Biologics (Cayman) Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

WuXi Biologics (Cayman)'s Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(210.922	+	423.308)	/	5027.096
	=	0.13

WuXi Biologics (Cayman)'s Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(178.81	+	539.068)	/	5269.693
	=	0.14

WuXi Biologics (Cayman) (OTCPK:WXXWY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

WuXi Biologics (Cayman) Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

WXIBF:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.